Anti-CTLA-4 antibodies with reduced ADCC function (IgG2, tremelimumab) have decreased activity [33,34], whereas afucosylated Fc domains with increased ADCC demonstrate enhanced anti-tumor activity [35]. The gene discussed is CTLA4; the disease is neoplasm.